Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Coursera outlines $805M-$815M 2026 revenue target as Udemy merger and AI initiatives accelerate platform evolution

View original at seekingalpha.com
Coursera outlines $805M-$815M 2026 revenue target as Udemy merger and AI initiatives accelerate platform evolution Earnings Call Insights: Coursera, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Coursera delivered a strong fourth quarter with full-year revenue of $757 million, a 9% increase year-over-year

    80% confidence
  • We do expect to continue to make improvements and progress on gross margin in the aggregate

    80% confidence
  • The platform offered more than 13,500 courses, expanding the catalog by over 45% year-over-year, the fastest pace in the past 5 years

    80% confidence
  • We anticipate revenue to be in the range of $805 million to $815 million for full year 2026, representing growth of approximately 6% to 8% from the prior year

    80% confidence
  • The Udemy merger is an important step in accelerating Coursera's strategy and reinforcing the shift toward a leading technology platform for skills

    80% confidence
  • Partner feedback on the Udemy merger has been generally positive with questions about integration

    80% confidence
  • We won't be happy with our NRR number until it's frankly above 100%

    80% confidence
  • The company achieved record free cash flow of $78 million, up 32%

    80% confidence
  • For the full year, net income was $67 million or 8.8% of revenue and adjusted EBITDA was $64 million, representing an 8.4% margin

    80% confidence
  • The new 15% platform fee will gradually benefit margins, with initial expansion in the Consumer segment in the second half of 2026 and Enterprise margin improvement expected in 2027

    80% confidence
  • The platform fee is expected to provide a structural benefit to gross margin over time

    80% confidence
  • Consumer segment growth is projected at more than 10% for 2026, with Enterprise expected to grow in the low single digits

    80% confidence
  • Q4 delivered total revenue of $197 million, up 10% from the prior year period, driven by growth across both Consumer and Enterprise segments

    80% confidence
  • Traffic from AI platforms is described as early days with higher-intent traffic but no substantive data yet

    80% confidence
  • Guidance for Udemy merger closing remains the second half of the year but acknowledged a wide range of possible outcomes

    80% confidence
  • The total number of paid Enterprise customers increased to 1,730, up 7% from a year ago, and net retention rate for paid enterprise customers was 93%

    80% confidence
  • There is no change to Consumer pricing or Enterprise pricing from the platform fee

    80% confidence
  • The platform fee is to enable us to invest in an ongoing way in continuing to improve the platform

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com